NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biopharmaceuticals’

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

7 February 2014

Venture capital-backed Auspex prices IPO at $12 per share

shares stocks IPO Venture capital-backed biopharmaceutical company Auspex Pharmaceuticals has priced its IPO on the Nasdaq exchange at $12 per share.

11 December 2013

Life science venture capital firm Pappas Ventures hires Roche chairman Franz Humer

Life science venture capital firm Pappas Ventures has appointed Franz Humer, chairman of pharmaceutical giant Roche, as a venture partner and senior advisor with the firm.

4 December 2013

Biotech company Zafgen raises $45m Series E

biotech_lrg Biopharmaceutical business Zafgen has raised $45m in a Series E round to fund the development of its obesity therapeutic beloranib.

25 November 2013

BC Partners, Onex to bid for venture capital-backed Ikaria

biotech_lrg Private equity firms BC Partners, Onex Corp and American Securities are reportedly set to make second round bids for specialty drug business Ikaria.

20 November 2013

Venture capital-backed Moderna Therapeutics secures $110m

dollar envelope money Biotech startup Moderna Therapeutics has raised a $110m round, which took its fundraising total to $415m.

1 November 2013

NovaQuest Capital Management raises $459m for new fund

biomed_lrg Private equity firm NovaQuest Capital Management has held a final close of $459m for its new fund, which will provide financing to biopharmaceutical businesses.

16 September 2013

Select BioVenture Partners seeks $200m for bioscience fund

Florida-based Select BioVentures is seeking $200m for its current fund. The vehicle will target Florida-based bioscience companies with an emphasis on late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. The firm is comprised of strategic and operating consultancy The Sage Group and three former C-level professionals with[...]


Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014